Search Results

The Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster, Helmholtz Munich, and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that the first patient has been dosed in an investigator-initiated trial with ITM’s radiopharmaceutical drug candidate, ITM-31 for the potential use in glioblastoma patients.

Biocrates Life Sciences AG, the global leader in targeted metabolomics, and Helmholtz Zentrum München, the German Research Center for Environmental Health, enter a new phase of collaboration in their 10-year partnership.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of Neurosurgery and Nuclear Medicine at the University Hospital Münster announced the start of a Phase I clinical trial with ITM’s drug candidate ITM-31, a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma.

Phio Pharmaceuticals Corp. announced that is has entered into a research collaboration with the Helmholtz Zentrum München.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and Helmholtz Munich, announced a cooperation agreement for the clinical development of a radiopharmaceutical therapy candidate to treat malignant brain tumor glioblastoma.

Phio Pharmaceuticals Corp. today announced that its research partner, Helmholtz Munich, presented preclinical data showing that Phio’s lead clinical product PH-762.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has reached a new agreement with Medigene AG (“Medigene”) in relation to

The Helmholtz Association is funding a new Helmholtz Zentrum München spin-off with roughly 115,000 euros.